Clinical trial · Observational
Evaluation of Gynecological and Sexual Sequelae
Evaluation of Gynecological and Sexual Sequelae in Patients Treated for Rectal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Rectal cancer accounts for approximately 40% of colorectal cancers. In France, there are 15,000 new cases per year, and the 5-year survival rate is 55% across all stages. Treatment involves surgical resection of the rectum, often combined with preoperative chemoradiotherapy and sometimes immunotherapy, depending on the tumor's immunohistochemical status. This treatment strategy has improved recurrence-free survival but is associated with long-term functional complications affecting the digestive, urological, gynecological, and sexual systems. Surgery causes anatomical changes and damage to the autonomic nervous system plexuses. Radiotherapy, for its part, causes pelvic inflammation with the development of fibrosis and potential vascular and nerve damage. Various disorders can arise as a result of these anatomical changes, such as erectile dysfunction in men; dyspareunia and vaginal dryness in women; urinary incontinence and impaired sexual quality of life in both sexes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rectal Cancer Patients | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Prevalence of gynecological and sexual sequelae in women after treatment for rectal cancer
- description
- The prevalence and characterization of gynecological and sexual sequelae in women after treatment for rectal cancer will be carried out on the basis of questionnaires under study (FSFI, QLQ-CR29, QLQ-C30 and the GynéRect questionnaire) completed during the single follow-up visit.
Primary outcomes (2)
- measure
- To assess the prevalence of sexual dysfunctions and gynecological sequelae in women after treatment for rectal cancer.
- timeFrame
- 1 day
- description
- Evaluation of the prevalence of sexual dysfunctions and gynecological sequelae after treatment in women for rectal cancer, assessed using a standardized questionnaire combining validated questionnaires (FSFI, QLQ-C30, QLQ-CR29) and a specific GynéRect module for phenotyping disorders
- measure
- To assess the characteristics of sexual dysfunctions and gynecological sequelae in women after treatment for rectal cancer.
- timeFrame
- 1 day
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Women aged 18 to 60 at the time of diagnosis * Having been treated for rectal cancer between 2020 and 2025 * Cancer in remission * Having been sexually active before receiving treatment for their rectal cancer * Having completed the various questionnaires during their treatment Exclusion Criteria: * Inability to complete questionnaires (cognitive impairment, language barrier) * Pregnant women * Women with active cancer and/or undergoing chemotherapy * Women with a history of extensive gynecological surgery * Individuals deprived of their liberty by an administrative or judicial decision, or individuals under legal protection/guardianship or curatorship * Individuals without social security coverage
References
Publications (0)
Data not yet available